Company: KROS
Filing Date: 2025-05-27
Form Type: DEFA14A
Source: 0001104659-25-052890
Chunk: 3

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-27
Form: DEFA14A
Chunk 3
---
’s CEO. This includes four representatives of Keros stockholders, two of whom are representatives
of Pontifax, the Company’s second largest stockholder. Collectively, the Board represents diverse perspectives and brings significant
experience across the biotechnology industry, including drug development and commercialization, capital allocation, M&A and business
development. In short, Keros has the right Board to oversee the ongoing strategic review process to maximize stockholder value and execute
on the ultimate outcome of that process.

The Board remains focused on successfully completing the
strategic alternatives review process, which remains ongoing. We have always made, and will continue to make, decisions that we believe
are in the best interests of the Company and ALL stockholders

We strongly urge you to vote “FOR” each of Keros’ three director nominees, Mary Ann Gray, Ph.D., Ran Nussbaum and Alpna Seth, Ph.D.

| YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY SHARES                                
 YOU OWN.                                                                         
 YOU MAY VOTE BY TELEPHONE, THE INTERNET OR                                       
 MAIL BY FOLLOWING THE INSTRUCTIONS ON THE PROXY CARD. WE URGE YOU TO VOTE TODAY! 
 If you have any questions or require any assistance                              
 with voting your shares, please contact:                                         
 7 Penn Plaza                                                                     
 New York, New York 10001                                                         
 Toll-Free: 1-800-322-2885                                                        
 Or                                                                               
 Email: proxy@MacKenziePartners.com                                               |

Goldman Sachs & Co. LLC is serving as Keros’ financial
advisor, and Cooley LLP is serving as legal counsel.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing
and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of
the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master
regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue.
By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful
and potentially disease-modifying benefit to patients. One of Keros’ product candidates, cibotercept (KER-012), is being developed
for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ second